Oncosil Medical Ltd (OSL:ASX)

8.0¢

right-arrow Created with Sketch. -0.001 (-1.23%)
MCAP $63.78M
Last trade 16.10pm 17/05/2021 20mins delayed

Latest Announcements

10/05/2021OSLOncosil Medical Ltd
10/05/2021OSLOncosil Medical Ltd
04/05/2021 Price SensitivePSOSLOncosil Medical Ltd
29/04/2021 Price SensitivePSOSLOncosil Medical Ltd
01/03/2021OSLOncosil Medical Ltd
26/02/2021OSLOncosil Medical Ltd
23/02/2021 Price SensitivePSOSLOncosil Medical Ltd
23/02/2021 Price SensitivePSOSLOncosil Medical Ltd

Company Overview

OncoSil Medical Limited is a late-stage medical device company, which is focused on localized treatments for patients with pancreatic and liver cancer. The Company is engaged in the development of its lead product candidate, the OncoSil localized radiation therapy, for the treatment of pancreatic cancer. The Company's lead product, OncoSil, is a brachytherapy device that emits beta radiation and is implanted directly inside the cancerous tumor. OncoSil is a silicon and phosphorus (p32) beta emitter, able to be implanted intra-tumorally via endoscopic ultrasonography in localized solid tumors of patients with pancreatic cancer. The Company focuses on an application for Conformite Europeene (CE) Mark to enable commercial sales of OncoSil in the European Union and an application for an Investigational Device Exemption (IDE) from the United States Food and Drug Administration (FDA) to enable commencement of the United States pivotal clinical study, known as OncoPac-1.

OSL in the news

Search Previous Announcements